Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-κB inhibitor for pancreatic cancer in mice

Cancer Letters

Volumn 306, Issue 1, 2011, Pages 92-98

  Furukawa, Kenei ^a   Ohashi, Toya ^a   Haruki, Koichiro ^a   Fujiwara, Yuki ^a   Iida, Tomonori ^a   Shiba, Hiroaki ^a   Uwagawa, Tadashi ^a   Kobayashi, Hiroshi ^a   Yanaga, Katsuhiko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gene therapy; Nafamostat mesilate; NF B inhibitor; Pancreatic cancer; Tumor necrosis factor alpha

Indexed keywords

ADENOVIRUS VECTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NAFAMSTAT MESILATE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GUANIDINES; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NF-KAPPA B; PANCREATIC NEOPLASMS; SERINE PROTEINASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

ADENOVIRIDAE; MUS; MUS MUSCULUS;

EID: 79955463604     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.02.036     Document Type: Article

References (38)

1. Niederhuber J.E., Brennan M.F., Menck H.R. The National Cancer Date Base report on pancreatic cancer. Cancer 1995, 76:1671-1677.
2. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
3. Berlin J.D., Catalano P., Thomas J.P., Kugler J.W., Haller D.G., Benson A.B. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 2002, 20:3270-3275.
4. Old L.J. Tumor necrosis factor (TNF). Science 1985, 230:630-632.
5. Spriggs D.R., Sherman M.L., Michie H., Arthur K.A., Imamura K., Wilmore D., Frei E., kufe D.W. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion: a phase I and pharmacologic study. J. Natl. Cancer Inst. (Bethesda) 1988, 80:1039-1044.
6. Wang C.Y., Mayo M.W., Baldwin A.S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996, 274:784-787.
7. Chen F., Castranova V., Shi X. New insights into the role of nuclear factor-κB in cell growth regulation. Am. J. Pathol. 2001, 159:387-397.
8. Amer B.A., David B. An essential role for NF-κB in preventing TNF-alpha-induced cell death. Science 1996, 274:782-784.
9. Antwerp V.D.J., Seamus M.J., Tal K., Douglas G.R., Inder V.M. Suppression of TNF-alpha-induced apoptosis by NF-κB. Science 1996, 274:787-789.
10. Karin M., Lin A. NF-κB at the crossroads of life and death. Nature Immunol. 2002, 3:221-227.
11. Uwagawa T., Li Z., Zhe Chang., Xia Q., Peng B., Sclabas G.M., Ishiyama S., Hung M.C., Evans D.B., Abbruzzese J.L., Chiano P.J. Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death. Cancer 2007, 109:2142-2153.
12. Furukawa K., Iida T., Shiba H., Fujiwara Y., Uwagawa T., Shimada Y., Misawa T., Ohashi T., Yanaga K. Anti-tumor effect by inhibition of NF-κB activation using nafamostat mesilate for pancreatic cancer in a mouse model. Oncol. Rep. 2010, 24:843-850.
13. Fujii S., Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, kallikrein and trypsin. Biochim. Biophys. Acta 1981, 661:342-345.
14. Aoyama T., Ino Y., Ozeki M., Oda M., Sato T., Koshiyama Y., Suzuki S., Fujita M. Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn. J. Pharmacol. 1984, 35:207-227.
15. Iwaki M., Ino Y., Motoyoshi A., Ozeki M., Sato T., Kurumi M., Aoyama T. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn. J. Phamacol. 1986, 41:155-162.
16. Takahashi H., Takizawa S., Tatewaki W., Nagai K., Wada K., Hanano M., Shibata A. Nafamostat mesilate (FUT-175) in the treatment of patients with disseminated intravascular coagulations. Thomb. Haemost. 1989, 62:372.
17. Ohtake Y., Hirasawa H., Sugai T., Oda S., Shiga H., Matsuda K., Kitamura N. Nafamostat mesilate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contr. Nephrol. 1991, 93:215-217.
18. Muto S., Imai M., Asano Y. Effect of nafamostat mesilate on Na+ and K+ transport properties in the rabbit cortical collecting duct. Br. J. Pharmacol. 1993, 109:673-678.
19. Muto S., Imai M., Asano Y. Mechanisms of the hyperkalemia caused by nafamostat mesilate: effects of its two metabolites on Na+ and K+ transport properties in the rabbit cortical collecting duct. Br. J. Pharmacol. 1994, 111:173-178.
20. Kitagawa H., Chang H., Fujita T. Hyperkalemia due to nafamostat mesylate. N. Engl. J. Med. 1995, 332:687.
21. Kanegae Y., Lee G., Sato Y., Tanaka M., Sakaki T., Sugano S. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific cre recombinant. Nucl. Acids Res. 1995, 23:3816.
22. Niwa H., Yamamura K., Miyazaki Y. Efficient selection for high expression transfectants with a novel eukaryotic vector. Gene 1991, 108:193.
23. Kanegae Y., Makimura M., Saito I. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn. J. Med. Sci. Biol. 1994, 47:157-166.
24. Shimada Y., Fukuda T., Aoki K., Yukawa T., Iwamuro S., Ohkawa K., Takada K. A protocol for immunoaffinity separation of the accumulated ubiquitin-protein conjugates solubilized with sodium dodecyl sulfate. Anal. Biochem. 2008, 377:77-82.
25. Marr R.A., Hitt M., Muller W.J., Gauldie J., Graham F.L. Tumour therapy in mice using adenovirus vectors expressing human TNFα Int. J. Oncol. 1998, 12:509-515.
26. Murugesan S.R., King C.R., Osborn R., Fairweather W.R., O'Reilly E.M., Thornton M.O., Wei L.L. Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer. Cancer Gene Ther. 2009, 16:841-847.
27. Yamini B., Yu X., Gillespie G.Y., Kufe D.W., Weichselbaum R.R. Transcriptional targeting adenovirally delivered tumor necrosis factor α by temozolomide in experimental glioblastoma. Cancer Res. 2004, 64:6381-6384.
28. M. Posner, K.J. Chang, A. Rosemurgy, J. Stephenson, M. Khan, T. Reid et al. Multi-center, phase 2/3, randomized, controlled clinical trial using TNFerade gene delivery combined with chemoradiation in patients with locally advanced pancreatic cancer (LPAC). Poster presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, 2007.
29. Zhang Y., Gavriil M., Lucas J., Mandiyan S., Follettie M., Diesl V., Sum F.W., Powell D., Haney S., Abraham R., Arndt K. IkappaBalpha kinase inhibitor IKI-1 conferred tumor necrosis factor alpha sensitivity to pancreatic cancer cells and a xenograft tumor model. Cancer Res. 2008, 68:9519-9524.
30. McDade T.P., Perugini R.A., Vittimberga F.J., Carrigan R.C., Callery M.P. Salicylates inhibit NF-kappaB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cancer cells. J. Surg. Res. 1999, 83:56-61.
31. Wang C.Y., Cusack J.C., Liu R., Baldwin A.S. Control of inducible chemoresistance. enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 1999, 5:412-417.
32. Patel N.M., Nozaki S., Shortle N.H., Bhat-Nakshatri P., Newton T.R., Rice S., Gelfanov V., Boswell S.H., Goulet R.J., Sledge G.W., Nakshatri H. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 2000, 19:4159-4169.
33. Wang W., McLeod H.L., Cassidy J. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int. J. Cancer 2003, 104:504-511.
34. Yeh P.Y., Chuang S.E., Yeh K.H., Song Y.C., Ea C.K., Cheng A.L. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochem. Pharmacol. 2002, 63:1423-1430.
35. Arlt A., Gehrz A., Müerköster S., Vorndamm J., Kruse M.L., Fölsch U.R., Schäfer H. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003, 22:3243-3251.
36. Banerjee S., Zhang Y., Ali S., Bhuiyan M., Wang Z., Chiao P.J., Philip P.A., Abbruzzese J., Sarkar F.H. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res. 2005, 65:9064-9072.
37. Uwagawa T., Chiano P.J., Gocyo T., Hirohara S., Misawa T., Yanaga K. Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-κB activation. Anticancer Res. 2009, 29:3173-3178.
38. Uwagawa T., Misawa T., Sakamoto T., Ito R., Gocho T., Shiba H., Wakiyama S., Hirohara S., Sadaoka S., Yanaga K. A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Ann. Oncol. 2009, 20:239-243.